Martin S. Zand, Principal Investigator

NIH
5R01 AI069351-03
Zand PI
Branching Stochastic Process Modeling of Human Plasma Cell Differentiation
05/15/07-04/30/11
DHHS/PHS/NIH
N01-A1-50020
University of Rochester Center for Biodefense Immune Modeling- Lab3
09/30/05-09/29/10
DHHS/PHS/NIH
HHSN26620050029C
(N01-AI-50029)
Immune Function and Biodefense in Children, Elderly and Immunocompromised Populations (Modeling)
05/15/07-04/30/11

Dr. Zand's research program is focused the role of B cells in alloimmune responses in solid organ transplantation and the adaptive immune response to biopathogens. NIH funded work includes:

  1. Branching Stochastic Process Modeling of Human Plasma Cell Differentiation where he is PI and involves mathematical modeling of plasma cell differentiation using data generated from an in vitro system and then to using the model to generate hypothesis regarding clinical treatments which might prevent memory B cell and plasma cell development in kidney transplantation.
  2. The Center for Biodefense Immune Modeling, where Dr. Zand serves as co-PI and his research includes murine models of the adaptive immune response to influenza, including computer and mathematical modeling.
  3. Rochester Program for Biodefense of Immunocompromised Populations (Investigator). The goal of this study is to examine immune responses in anti-TNF treated rheumatoid arthritis patients to influenza A vaccination. Dr. Zand's work is to create stochastic, discrete event models of this immune response.
  4. Predictive Mathematical Models for Rational Design of Chemoimmunotherapy of Leukemia (investigator). The goal of this study is to create differential equation models of the graft-versus-leukemia response that predict the effects of chemotherapy in the competition between leukemia-specific CD8 effectors and the tumor. Industry funded translation research includes: CXCR4 inhibition and polyclonal anti-thymocyte globulin for immune desensitization. The goal of this study is to determine if allo-reactive plasma cells can be mobilized from the bone marrow and made vulnerable to induction of apoptosis with polyclonal anti-thymocyte globulin.

In addition, members of the Nephrology Faculty are involved in a number of industry sponsored studies.